Exelixis, Inc. (EXEL) Stock: Price, Forecast & Analyst Target
Exelixis, Inc. (EXEL) — MoonshotScore 98/100 (Exceptional band), calculated Nov 18, 2026. Price $64.63 (-1.82%), as of the Nov 20, 2026 trading session; market cap $15.8B.
Educational signal · not a buy or sell recommendation · How to read this
Exelixis, Inc. · EXEL · NASDAQ · Healthcare · Biotechnology
Research dated 2026-09-13: Exelixis is an oncology drug developer with an established commercial franchise, not a biotechnology company waiting for its pipeline to produce meaningful revenue. The case rests on whether CABOMETYX can keep expanding product economics while research spending builds therapies capable of reducing dependence on cabozantinib.
Price as of Nov 20, 2026
Key Statistics
MoonshotScore v2 · Exelixis (EXEL)
ExceptionalWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Elite quality, a fortress balance sheet and elite growth, but a full valuation; the market is already moving on it. Business Quality: Elite; Financial Safety: Fortress; Valuation: Full; Growth Durability: Compounding; Momentum: Surging.
- EPS beat 0 of the last 4 reports
- Altman Z 17.86 · Piotroski F 6
- ROE 44.3% · ROA 23.5% · current ratio 3.21
Helping: business quality, balance-sheet strength, durable growth, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 98 | Exceptional | |
| 98 | Exceptional | |
| 98 | Exceptional | |
| 98 | Exceptional | |
| 98 | Exceptional | |
| 98 | Exceptional |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $64.63 | |
| Change on the day | -1.82% | |
| 52-week range | $39.71–$73.69 | |
| Market capitalisation | $15.8B | — |
| Price / earnings (trailing) | 19.86 | |
| Shares traded on the day | 2.04M | |
| Beta (volatility vs the S&P 500) | 0.42 |
Price & events
Point at or tab to any week for its close.
Other perspectives
Council score for Exelixis (EXEL): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 6 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 19, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Nov 19, 2026, the Munger lens read the price at that time as overvalued against its own estimate of value.
Readings on this page are from Nov 21, 2026, except a card that shows its own read date.
What is Exelixis (EXEL), and what does it report?
Short answer · as of
Exelixis discovers, develops and markets cancer medicines, led by CABOMETYX and COMETRIQ, which share cabozantinib as their active compound.
Research dated 2026-09-13.
Its portfolio also includes partnered products, while its development work spans kinase inhibitors and an antibody-drug conjugate for solid tumors and other cancers.
Reported revenue is not a pure royalty stream. Product sales supply the dominant contribution, supplemented by license and collaboration revenue, so changes in prescribing demand matter directly alongside milestones and partner economics.
What do the latest results show for Exelixis (EXEL)?
Research dated 2026-09-13.
Revenue and gross profit continued to rise in the latest period, while operating profit eased despite the higher top line. Research and commercial spending increased, showing that incremental revenue did not flow through untouched, although net income remained strong and diluted earnings stayed well above earlier periods.
Recent earnings have generally exceeded expectations even when revenue has occasionally fallen short. That pattern points to expense control and high product gross margins as important contributors to earnings delivery, rather than revenue surprises alone.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | Not available | Not available | Not available | Not available |
| Jun 30, 2026 | Not available | Not available | Not available | Not available |
| Mar 31, 2026 | Not available | Not available | Not available | Not available |
| Dec 31, 2025 | Not available | Not available | Not available | Not available |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Sep 2025 | $598M | $194M | $0.69 (diluted) |
| Dec 2025 | $599M | $245M | $0.88 (diluted) |
| Mar 2026 | $611M | $210M | $0.79 (diluted) |
| Jun 2026 | $629M | $212M | $0.82 (diluted) |
What are the financial strengths and risks for Exelixis (EXEL)?
Short answer
Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.
Research dated 2026-09-13.
Exelixis combines sustained profitability with substantial operating cash generation and modest capital expenditure. Cash and investments comfortably exceed debt and total liabilities, giving the company room to fund development without relying on near-term external financing.
The balance sheet is stronger than the movement in cash and short-term investments alone suggests because a meaningful portion of liquidity sits in longer-term investments. Even so, the shorter-duration balance has declined across the reported window, so continued cash generation matters as research and commercial spending remain substantial.
The business risk is concentration: product revenue dominates, and the commercial portfolio is anchored by medicines derived from cabozantinib. A deterioration in that franchise could pressure revenue, profit and internally funded pipeline investment at the same time.
What should you watch next at Exelixis (EXEL)?
Short answer · as of
Analyst estimates on file carry FY2027 revenue $2.56B · EPS 3.71 · 12 analysts.
Research dated 2026-09-13.
Watch whether CABOMETYX-led product revenue keeps rising while operating profit resumes growth. The latest period paired a stronger top line with higher research and selling costs, making expense absorption as informative as headline revenue.
Operating cash flow should remain aligned with reported profit, and the mix between short-term cash and longer-term investments deserves attention when judging financial flexibility. Pipeline progress matters most where it can broaden the franchise beyond cabozantinib rather than merely add spending.
The scheduled earnings release carries expectations for further revenue and earnings growth. The useful comparison will be against the recent pattern of steady revenue expansion, resilient margins and earnings delivery that has often surpassed forecasts.
What the records here don't tell us
- The next earnings date is not yet scheduled in the calendar we read.
Checked against the records this page reads, on the dates shown above.
How does Exelixis compare with its peers?
Short answer
Exelixis's score ranks 1st of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13.
Exelixis differs from development-stage biotechnology companies because marketed oncology products already support profit, cash generation and ongoing research. It also differs from broadly diversified pharmaceutical groups: commercial exposure is concentrated around cabozantinib, while license and collaboration arrangements extend the portfolio and geographic reach.
That combination creates an unusual financial shape for biotechnology: very high gross margins, strong returns and low leverage alongside material research spending. The tradeoff is that current economics depend heavily on an established franchise while the pipeline carries the burden of diversification.
| Company | Price | Market value | Score |
|---|---|---|---|
| Exelixis (EXEL) — this page | $64.63 | $15.8B | 98 |
| $559.10 Nov 19, 2026 | $23.8B | 97 5-pillar Nov 18, 2026 | |
| $255.96 Nov 19, 2026 | $16.8B | 96 5-pillar Nov 18, 2026 | |
| $315.82 Nov 19, 2026 | $9.36B | 96 5-pillar Nov 18, 2026 | |
| $156.59 Nov 19, 2026 | $15.9B | 95 5-pillar Nov 18, 2026 | |
| $91.35 Nov 20, 2026 | $10.4B | 95 5-pillar Nov 18, 2026 | |
| $72.67 Nov 20, 2026 | $11.4B | 92 5-pillar Nov 18, 2026 | |
| $115.87 Nov 19, 2026 | $23.6B | 91 5-pillar Nov 18, 2026 | |
| $64.88 Nov 19, 2026 | $9.81B | 90 5-pillar Nov 18, 2026 | |
| $124.02 Nov 19, 2026 | $8.09B | 88 5-pillar Nov 18, 2026 | |
| $159.68 Nov 19, 2026 | $11.3B | 83 5-pillar Nov 18, 2026 | |
| $147.82 Nov 19, 2026 | $19.8B | 72 5-pillar Nov 18, 2026 | |
| $396.74 Nov 19, 2026 | $9.22B | 35 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $49.00 – $65.00
- Consensus target
- $54.20
- Median target
- $52.50
- Revenue estimate
- $2.56B
- EPS estimate
- $3.71
Consensus record · Captured .
Measured against a quoted price of $64.63 (as of Nov 20, 2026).
Insider activity
Form 4 records via FMP · Of the newest 60 records, those within the last 180 days, newest dated Aug 10, 2026
- Transactions
- 14
- Identified insiders
- 11
- Purchases
- 0
- Sales
- 4
- Other transactions
- 10
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held EXEL in their latest 13F filing, and what they did against the filing before it.
| Investor | Manager | 13F quarter | Portfolio weight | Value | Last quarter |
|---|---|---|---|---|---|
| Bridgewater Associates | Founded by Ray Dalio | Q3 2026 | 0.08% | $19.19M | Trimmed −18.0% shares |
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Exelixis (EXEL)?
EXEL Healthcare Stock FAQ
Research dated 2026-09-13; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
Why is CABOMETYX so important to Exelixis?
CABOMETYX is a marketed cabozantinib therapy and sits at the center of a product-led revenue base. Its commercial durability helps determine how much profit and cash Exelixis can direct toward pipeline development.
How are CABOMETYX and COMETRIQ related?
CABOMETYX and COMETRIQ are distinct marketed formulations derived from cabozantinib, a compound that inhibits several kinases involved in tumor biology. Their shared origin makes cabozantinib central to the current commercial portfolio.
Do license and collaboration payments drive Exelixis revenue?
Product sales are the dominant reported revenue source, while license and collaboration revenue provide additional contributions. Exelixis therefore has direct commercial exposure rather than relying mainly on partner payments.
Can Exelixis fund its oncology pipeline internally?
Strong operating cash flow, minimal capital needs and liquidity well above debt support internal research funding. Continued CABOMETYX-led cash generation remains important because research spending is substantial and the shorter-duration cash balance has declined across the reported window.
What is the EXEL stock price today?
The last price recorded for Exelixis, Inc. (EXEL), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the EXEL price target?
The analyst consensus price target for Exelixis, Inc. (EXEL), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 27 figures on this page — 1 from SEC filings and earnings calls, 19 from Financial Modeling Prep (FMP), 6 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources (as of 2026-09-13), by section of the research
ETFs that hold EXEL
Funds in our ETF coverage that list EXEL among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| ERShares Private-Public Crossover ETF (XOVR) | 3.23% |